Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated â NIVACOR trial (GOIRC-03-2018)
Damato, Angela, Iachetta, Francesco, Antonuzzo, Lorenzo, Nasti, Guglielmo, Bergamo, Francesca, Bordonaro, Roberto, Maiello, Evaristo, Zaniboni, Alberto, Tonini, Giuseppe, Romagnani, Alessandra, BerselТом:
20
Журнал:
BMC Cancer
DOI:
10.1186/s12885-020-07268-4
Date:
December, 2020
Файл:
PDF, 537 KB
2020
File converter
Більше результатів пошуку
More benefits 
